ABSTRACT
The pathophysiology of type 2 diabetes mellitus conveys increased cancer risk, and any antidiabetic drug may alter that risk in a favorable or unfavorable way. This article discusses the links between diabetes and cancer, the different agents available for treating diabetes, and the cancer risk associated with these therapies.
- Copyright © 2014 The Cleveland Clinic Foundation. All Rights Reserved.
- Grace E. Ching Sun, DO⇑,
- Sangeeta R. Kashyap, MD and
- Christian Nasr, MD
- Department of Medicine, Section of Endocrinology & Metabolism, Assistant Professor of Medicine, Louisiana State University Health Sciences Center, Shreveport
- Endocrinology and Metabolism Institute, Cleveland Clinic; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- Endocrinology and Metabolism Institute, Cleveland Clinic
- ADDRESS:
Grace E. Ching Sun, DO, Department of Medicine, Section of Endocrinology & Metabolism, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130; e-mail: gsun1{at}lsuhsc.edu
ABSTRACT
The pathophysiology of type 2 diabetes mellitus conveys increased cancer risk, and any antidiabetic drug may alter that risk in a favorable or unfavorable way. This article discusses the links between diabetes and cancer, the different agents available for treating diabetes, and the cancer risk associated with these therapies.
- Copyright © 2014 The Cleveland Clinic Foundation. All Rights Reserved.